BLAC stock icon

Bellevue Life Sciences Acquisition Corp
BLAC

Market Cap: $43.8M

 

About: Bellevue Life Sciences Acquisition Corp is a blank check company.

Healthcare Surgical & Medical Instruments & Apparatus
0
Funds holding %
of 6,710 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

16.5% less ownership

Funds ownership: 35.0% [Q1] → 18.5% (-16.5%) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

38% less funds holding

Funds holding: 24 [Q1] → 15 (-9) [Q2]

47% less capital invested

Capital invested by funds: $33.9M [Q1] → $18.1M (-$15.8M) [Q2]

90% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 10

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BLAC.

See Analyst Rankings

Financial journalist opinion

Neutral
PRNewsWire
3 months ago
Bellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at May 14, 2024 Stockholder Meeting
BELLEVUE, Wash. , May 13, 2024 /PRNewswire/ -- As previously announced, on May 10, 2024, Bellevue Life Sciences Acquisitions Corp. (Nasdaq: BLAC) ("BLAC") convened a special meeting of stockholders (the "Special Meeting"), adjourned the Special Meeting without any business being conducted, and announced that the Special Meeting will be reconvened at 9:00 a.m.
Bellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at May 14, 2024 Stockholder Meeting
Neutral
PRNewsWire
4 months ago
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
SEOUL, South Korea , April 22, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical development resources and launch a strategic collaboration between the two companies. Through the MOU, the two companies will explore various ways to collaborate to create synergies between current platform technologies and new drug candidates.
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
Neutral
PRNewsWire
9 months ago
OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.
BELLEVUE, Wash. and SEOUL, South Korea , Nov. 16, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC), a publicly traded special purpose acquisition company ("BLAC"), and OSR Holdings Co., Ltd.
OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.
See News Rankings